ClinicalTrials.gg
Not yet recruitingNCT07859293Updated Oct 5, 2026

An Extension Trial of Asedebart in Participants With Congenital Adrenal Hyperplasia

A Phase 2 interventional study of Asedebart in Adrenal Hyperplasia, Congenital, sponsored by H. Lundbeck A/S. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Treatment

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The main goal of the trial is to study the long-term safety, how well people can handle the treatment, and how asedebart acts in the body and affects the body when used to treat classic congenital adrenal hyperplasia (CAH). The trial will include participants who have previously received asedebart in trial 19873A (NCT05669950).

02

Conditions studied

  • Adrenal Hyperplasia, Congenital

Keywords

  • CAH
  • asedebart
  • Lu AG13909
03

In context

Adrenal Hyperplasia, Congenital

101 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 28 are open to participants now.

This study's planned enrollment of 45 is above the median of 37 across 50 interventional studies indexed under Adrenal Hyperplasia, Congenital.

Browse Adrenal Hyperplasia, Congenital studies →

Lead sponsor

H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The participant has been treated with asedebart in a clinical trial.
  • The participant had an acceptable benefit-risk assessment in the prior trial and would benefit from continued treatment with asedebart in the opinion of the investigator.
  • For participants with > 12 weeks since their last dose of asedebart: The participant has been on a stable daily dose of GC replacement therapy of ≥ 8 milligram per square meter (mg/m\^2) (adjusted for body surface area in hydrocortisone equivalent dosage [HCe]) for >= 1 month prior to the Screening Visit.
  • For participants with > 12 weeks since their last dose of asedebart: The participant is not adequately controlled on their current treatment and, at the Screening/Baseline Visit, has either:

    • elevated androgen blood concentrations (A4 > (ULN) for age and sex) in morning measurements (pre-GC replacement dose) OR
    • androgen blood concentrations within the reference range (A4 \<= ULN for age and sex) and is being treated with supraphysiological GC (GC daily dose > 13 mg/m\^2 adjusted for body surface area in HCe)

Key Exclusion Criteria:

  • The participant has known or intolerance to asedebart or its .
  • The participant has taken any medicinal product (IMP) other than asedebart \< 3 months or \< 5 half-lives, whichever is longer, prior to the first dose of asedebart in this trial.
  • The participant is pregnant, breastfeeding, intends to become pregnant, or is of and not willing to use adequate methods.
  • The participant has an increased risk of adrenal crisis in the opinion of the investigator (for example history of repeated adrenal crisis in recent years, history of adrenal crisis caused by reduction of GC dose).

Other protocol-defined criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Asedebart

    Participants will receive asedebart per a prespecified dosing schedule.

    Drug: Asedebart

Interventions

  • Solution for injection/infusion

    Also known as: Lu AG13909

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to 42 months

Secondary outcomes

  1. Serum Concentration of Asedebart

    Time frame: Up to 42 months

  2. Area Under the Asedebart Serum Concentration-time Curve in a Dosing Interval (AUC0-tau)

    Time frame: Up to 73 days

  3. Area Under the Asedebart Serum Concentration-time Curve From Start of Injection to 28 days Post-dose (AUC0-4W)

    Time frame: Up to 73 days

  4. Maximum Observed Serum Concentration of Asedebart (Cmax)

    Time frame: Up to 73 days

  5. Nominal Time Corresponding to the Occurrence of Cmax of Asedebart (Tmax)

    Time frame: Up to 73 days

  6. Minimum Observed Serum Concentration of Asedebart (Ctrough)

    Time frame: Up to 73 days

  7. Nominal Time Corresponding to the Occurrence of Ctrough (Ttrough)

    Time frame: Up to 73 days

  8. Number of Participants with Anti-drug Antibodies (ADAs) Following Dosing

    Time frame: Up to 42 months

  9. Relative Reduction from Baseline in Morning Concentrations of Androstenedione (A4) in Blood

    Time frame: Baseline, Month 12, 24, and 36

  10. Relative Reduction from Baseline in Morning Concentrations of 17-hydroxyprogesterone (17-OHP) in Blood

    Time frame: Baseline, Month 12, 24, and 36

  11. Relative Reduction from Baseline in Morning Concentrations of Glucocorticoid (GC) Daily Dose

    Time frame: Baseline, Month 12, 24, and 36

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jul 2031, 57 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Jul 31, 2031
CompletionEst.
Jul 31, 2031
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07859293
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jul 31, 2031 (estimated)
Completion
Jul 31, 2031 (estimated)
Last update
Oct 5, 2026

Study contacts

Email contact via H. Lundbeck A/S
Contact
HQ_Medinfo@Lundbeck.com
+45 36301311
Email contact via H. Lundbeck A/S
study director · H. Lundbeck A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asedebart

Start the discussion